Compare DexCom, Inc. (DXCM) vs Tesla, Inc. (TSLA) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Tesla (TSLA) trades at $396.01, up 0.32% with bearish technical signals despite recent earnings beats. The stock faces valuation concerns with a P/E ratio of 361.89 and declining profit margins, dropping from 15.49% in 2023 to 4% in 2025. Recent news highlights regulatory approval for driver-assistance software in Europe and a potential cheaper EV model, while technical indicators show resistance near $398-$408. Cash flow remains positive at $579 million in 2025, though investing outflows persist.

Outlook is mixed: long-term growth depends on autonomous driving and energy segments, but near-term risks include intense EV competition and high valuation. Analysts are divided with 39.5% buy ratings and a $409.26 consensus target, suggesting modest upside. Investors should weigh innovation potential against margin pressure and execution risks in a slowing auto market.